Eduardo García-Galea

Dr. Eduardo García-Galea

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2025 in Cancer Discovery
Verified
Journal Article
Open access
CACarlota Arenillas
Carlota Arenillas
LCLucía Celada
Lucía Celada
JRJosé Ruiz-Cantador
José Ruiz-Cantador
BCBruna Calsina
Bruna Calsina
DDDebayan Datta
Debayan Datta
RTRodrigo Toledo
Rodrigo Toledo
This study explores parallels between systemic hypoxia adaptation in high-altitude populations and tumorigenesis. We identified EPAS1, a gene critical for hypoxia adaptation in populations such as Tibetans and Sherpas, as playing a similar adaptive role in tumors arising under hypoxic conditions. Tumors from patients with chronic hypoxia displayed impaired DNA repair and frequent emergence of EPAS1 variants, with frequencies reaching up to 90%, echoing the positive selection seen in high-altitude dwellers. Mechanistically, EPAS1 gain-of-function mutations promote COX4I2 expression, reducing cellular oxygen consumption and supporting tumor proliferation in hypoxia. Analysis of clinical data from patients with hypoxia revealed tissue-specific and time-sensitive tumorigenic effects, particularly impacting oxygen-sensitive cells in the postnatal period. Our findings suggest that EPAS1-driven adaptation mechanisms in high-altitude populations provide a model for understanding tumor evolution under hypoxic stress, highlighting how genetic adaptations to diverse stressors in natural populations may yield insights into tumorigenesis and cancer progression. Significance: This study reveals a broad convergence in genetic adaptation to hypoxia between natural populations and tumors, suggesting that insights from natural populations could enhance our understanding of cancer biology and identify novel therapeutic targets. See related commentary by Lee, p. 875

19 May 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MAMaría Alsina
María Alsina
GVGuillermo Villacampa
Guillermo Villacampa
CACarlos E de Andrea
Carlos E de Andrea
AVAna Vivancos
Ana Vivancos
MPMariano Ponz-Sarvisé
Mariano Ponz-Sarvisé
IMIGNACIO MELERO
IGNACIO MELERO
Purpose: Immune checkpoint inhibitors combined with chemotherapy have provided successful results in patients with gastric and gastroesophageal junction (G/GEJ) cancers in the metastatic setting. Similar strategies have been explored in earlier stages. In this study, we present the final results of the phase II MONEO trial, which evaluated the addition of avelumab to neoadjuvant chemotherapy. Patients and Methods: Patients with untreated, resectable G/GEJ adenocarcinoma received neoadjuvant treatment with four cycles of avelumab plus the FLOT4 regimen, followed by surgery. Upon postoperative recovery, patients underwent four additional adjuvant cycles of the same combination, followed by avelumab monotherapy for up to 1 year. The primary endpoint was pathologic complete response rate. Sequential flow cytometry and cytokine determination were performed in peripheral blood, along with multiplex tissue immunofluorescence and RNA sequencing in tumor specimens. Results: Forty patients were enrolled, achieving a pathologic complete response rate of 21.1% (95% confidence interval, 10.0–37.0). The major pathologic response rate was 28.9%, more pronounced in patients with tumors expressing PD-L1 before treatment as measured by the combined positive score (cutoff, 10; 33.3% vs. 21.1%). The results propose several potential biomarkers considering tumor immune infiltrate, circulating immune cells, and cytokines. Eighty percent of patients experienced treatment-related grade ≥3 adverse events. Conclusions: The combination of avelumab plus the FLOT4 regimen showed relatively modest efficacy in resectable G/GEJ adenocarcinoma. Better results were observed in PD-L1 combined positive score ≥10% tumors. Exploratory biomarker analyses provide insights that may help to identify candidates most likely to benefit from chemoimmunotherapy as a neoadjuvant treatment.

12 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JRJavier Ros
Javier Ros
JHJosé María Ucha Hermida
José María Ucha Hermida
EGEduardo García-Galea
Eduardo García-Galea
PMPablo Gómez Mugarza
Pablo Gómez Mugarza
GMGiulia Martini
Giulia Martini
EEElena Elez
Elena Elez
Background: For patients with refractory metastatic colorectal cancer (mCRC), trifluridine/tipiracil (FTD–TPI) has been associated with a significant improvement in overall survival (OS). However, data are lacking regarding the activity of FTD–TPI in patients with BRAF-mutated mCRC. Methods: This retrospective, multicenter, international cohort included patients with BRAF-mutated mCRC treated with FTD–TPI in a real-life setting in Spain and Italy. Survival analysis was performed using Kaplan–Meier methods and Cox proportional hazard models and according to established prognostic groups: good prognosis characteristics (GPC; < 3 metastatic sites and time from metastases to FTD–TPI ≥ 18 months) and poor prognosis characteristics (PPC; ≥ 3 metastatic sites or time from metastases to FTD–TPI < 18 months). Results: In the 26 patients included, the median age was 61 years, 13 (50%) were female, and 20 (77%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 1. Fourteen (56%) patients had right-sided tumors, six (23%) had microsatellite instability tumors, and thirteen (50%) had liver metastases. Median progression-free survival was 2.3 months (95% CI 2.0–3.2), and median OS (mOS) was 6.6 months (95% CI 4.4–12.0). mOS was 7.6 vs. 4.2 months (HR 1.64, 95% CI 0.65–4.10, p = 0.3) for GPC and PPC patients, respectively. Exploratory analyses identified ECOG as the only feature associated with survival. The most frequent grade 3–4 adverse events were neutropenia (8%), anemia (8%), and asthenia (4%). Conclusions: Patients with BRAF mutant mCRC achieved modest benefits with FTD–TPI; however, patients with GPC and ECOG 0 achieved longer OS compared with those with PPC or ECOG 1–2, thus warranting further exploration in prospective cohorts.

2 May 2025
Verified
Other
Open access
CACarlota Arenillas
Carlota Arenillas
LCLucía Celada
Lucía Celada
JRJosé Ruiz-Cantador
José Ruiz-Cantador
BCBruna Calsina
Bruna Calsina
DDDebayan Datta
Debayan Datta
RTRodrigo Toledo
Rodrigo Toledo
Supplementary Tables Supplementary Table S1. Clinical and Tumoral Data from CCHD-PPGL patients. Supplementary Table S2. Selection inference in the PPGL (TCGA, non-CCHD) and CCHD-PPGL cohort. Supplementary Table S3. Cancer Cell Fraction of EPAS1 mutations in CCHD-PPGL and PPGL patients. Supplementary Table S4. Clonal Clustering of CCHD-PPGL tumor mutations, highlighting EPAS1 mutation, using Conipher. Supplementary Table S5. Clonal Clustering of PPGL tumor mutations (TCGA), highlighting EPAS1 mutation, using Conipher. Supplementary Table S6. Parallelism of EPAS1 genetic variant selection in high-altitude populations and human tumors. Supplementary Table S7. EPAS1 Frequencies of Denisovan AGGAA haplotype from 4,000 Han Chinese Population (https://www.biosino.org/pgghan2/index) compared with gnomAD cohort around the world. Supplementary Table S8. Genetic Instability Characteristics (MSI, CNA, TMB) from CCHD-PPGL and PPGL (TCGA) tumors. Supplementary Table S9. Data of 354 differentially expressed mitochondrial genes (from Human Mitocarta Database) between EPAS1MUT and EPAS1WT samples in patients with PPGL (TCGA). Supplementary Table S10. Gene expression profiling analysis from patients with hemoglobin disorders and 52 paragangliomas with various genotypes including 19 EPAS1 (including one tumor in duplicate), 6 SDHx, 2 SLC25A11, 6 VHL, 3 RET, 3 NF1, 1 MAX, 1 MAML3 and 11 unmutated paragangliomas (Mancini M et al. Br J Haematol, 2023). Supplementary Table S11. RNAseq Raw Counts from PC12 Cell line cultured under normoxia/hypoxia conditions. Supplementary Table S12. Tumor type and hypoxia onset in patients with CCHD-PPGL. Supplementary Table S13. O2 Saturation in CCHD patients with or without PPGL tumors. Supplementary Table S14. Heart surgery influence in tumor development in patients with CCHD-PPGL. Supplementary Table S15. Clinical features of tumors developed under hypoxia (CCHD-PPGL) and normoxia (non-CCHD-PPGL). Supplementary Table S16. Representation of clinical variables in patients with PPGL and CCHD-PPGL.

2 May 2025
Verified
Other
Open access
CACarlota Arenillas
Carlota Arenillas
LCLucía Celada
Lucía Celada
JRJosé Ruiz-Cantador
José Ruiz-Cantador
BCBruna Calsina
Bruna Calsina
DDDebayan Datta
Debayan Datta
RTRodrigo Toledo
Rodrigo Toledo
Supplementary Figure S1. Description of the CCHD-PPGL cohort of 27 individuals with CCHD who developed 38 PPGL tumors. Supplementary Figure S2. Summary of the clinical features of patients with CCHD-PPGL. Supplementary Figure S3. EPAS1 mutations are enriched in the hypoxic cohort of patients with CCHD-PPGL (88.8%) compared to the normoxic cohort of patients without CCHD-PPGL (4.5%). Supplementary Figure S4. EPAS1 clonality in PPGL tumor samples from TCGA(1–4) (patients without CCHD with PPGL in normoxic conditions). Supplementary Figure S5. No EPAS1 mutations were detected in carotid body PGL tumors. Supplementary Figure S6. Hierarchical cluster analysis of RNA sequencing data from EPAS1-mutated CCHD-PPGL tumors. Supplementary Figure S7. Convergent Evolution in Natural Populations and Human Tumors. Supplementary Figure S8. Evolutionary speed of EPAS1 selection in different cohorts. Supplementary Figure S9. Hematoxylin and eosin staining and immunohistochemistry for Chromogranin A (neuroendocrine tumors maker) and for mismatch repair (MMR) proteins in PPGL tumors. Supplementary Figure S10. Acquisition of EPAS1 mutation and subsequent selection in sympathetic PPGL tumors developed under systemic hypoxia. Supplementary Figure S11. Assessment of apoptosis marker in pheochromocytoma-derived cells upon expression of mutant EPAS1 genes or exposure to hypoxic conditions. Supplementary Figure S12. Increase levels of fumarate metabolite in EPAS1MUT PPGL tumors and increase levels of succinate metabolite in SDHxMUT PPGL tumors. Supplementary Figure S13. Decrease of fumarate hydratase/fumarase (FH) mRNA expression and increment of SDHB mRNA expression in EPAS1MUT/VHLMUT PPGL tumors when compared to EPAS1WT/VHLWT PPGL tumors, as well as to SDHxMUT PPGL tumors. Supplementary Figure S14. Decrease of FH mRNA expression in missense EPAS1-mutated tumors (n = 8) when compared to EPAS1-wild-type tumors (n = 170). Supplementary Figure S15. Elevated fumarate and succinate levels in EPAS1-Overexpressing PPGL cells. Supplementary Figure S16. Oxygen consumption and supply balance in the mitochondrial electron transport chain as an advantageous survival and proliferative mechanism. Supplementary Figure S17. Gene-level extremely positive selection on EPAS1 gene in systemic hypoxia. Supplementary Figure S18. Time-dependent effects of systemic hypoxia on oxygen-sensing tissues. Supplementary Figure S19. Specialization process of the HIF2α gene for adaptation to systemic hypoxia. Supplementary Figure S20. Proliferative advantage and increased sensitivity to HIF2α inhibition in HEK293T cells expressing the EPAS1 P405A/P531A double mutant. Supplementary Figure S21. Authentication of PPGL-derived PC12 cell line. Supplementary Figure S22. Full western blots shown in Fig. 3B. Supplementary Figure S23. Full western blots shown in Supplementary Fig S11.